Product Details

Tenofovir + Lamivudine + Efavirenz Tablets BP deliver a high-quality combination therapy that meets British Pharmacopoeia (BP) standards. This fixed-dose triple combination manages HIV-1 infection as a complete first-line antiretroviral regimen, combining dual reverse transcriptase inhibition with non-nucleoside reverse transcriptase inhibitor action in a single tablet.

The tablets combine:

• Tenofovir Disoproxil Fumarate, a nucleotide reverse transcriptase inhibitor (NtRTI) that blocks HIV viral replication by inhibiting reverse transcriptase enzyme activity,
• Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI) that suppresses HIV viral replication through the same reverse transcriptase inhibition pathway, and
• Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase to block viral replication through a distinct mechanism, completing the triple-drug regimen.

Doctors commonly prescribe this triple combination as a complete once-daily antiretroviral therapy (ART) regimen for HIV-1 infection management, reducing pill burden compared to separate individual medications. Hospitals, specialty clinics, and pharmacies rely on this formulation for its consistent quality and dependable therapeutic results. Our manufacturing process follows strict quality standards to guarantee high purity, accurate dosing, and reliable therapeutic efficacy in every batch.

Key Features

• BP-standard compliant fixed-dose triple combination therapy
• Provides complete first-line HIV-1 antiretroviral coverage in one tablet
• Delivers combined NtRTI, NRTI, and NNRTI antiretroviral action
• Maintains a high-purity, stable formulation
• Uses hygienic blister packaging for safe storage
• Suits hospital, specialty clinic, and pharmacy use